Tacrolimus: A new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation

Keyphrases

• Graft-versus-host Disease (GvHD) 100%
• Tacrolimus 100%
• Hematopoietic Stem Cell Transplantation 100%
• New Agents 100%
• Cyclosporine 36%
• Living Donor 36%
• Unrelated Donor Transplantation 27%
• Advanced Malignancies 18%
• Unrelated Donor 18%
• Advanced Disease 18%
• Gene Expression 9%
• Multi-center Randomized Study 9%
• Molecular Mechanism 9%
• Calcineurin 9%
• Transplantation 9%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 9%
• Whole Blood 9%
• Methotrexate 9%
• Poor Survival 9%
• Low Incidence 9%
• Immunosuppressive Activity 9%
• IL-2 Gene 9%
• Nephrotoxicity 9%
• Sibling Donor 9%
• Blood Levels 9%
• Survival Disparities 9%
• FK506 9%
• Phosphorylase 9%
• Immunophilin 9%
• Macrolide Lactone 9%

Immunology and Microbiology

• Graft-Versus-Host Disease 100%
• Tacrolimus 100%
• Hematopoietic Stem Cell Transplantation 100%
• Ciclosporin 33%
• Immunosuppressive Drug 8%
• Immunosuppressant 8%
• Gene Expression 8%
• Interleukin 2 8%
• Allogeneic Stem Cell Transplantation 8%
• Methotrexate 8%
• Blood Level 8%
• Drug Mechanism 8%
• Immunophilin 8%